原发性气管支气管腺样囊性癌的研究进展  

Research progress of primary tracheobronchial adenoid cystic carcinoma

作　　者：李恩喜[1] 宋飞雪[1] LI Enxi;SONG Feixue(Department of Oncology,Lanzhou University Second Hospital,Gansu Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院肿瘤内科,甘肃兰州730030

出　　处：《现代肿瘤医学》2024年第12期2292-2297,共6页Journal of Modern Oncology

摘　　要：原发性气管支气管腺样囊性癌(primary tracheobronchial adenoid cystic carcinoma, TACC)是一种罕见的非小细胞肺癌,仅占所有肺恶性肿瘤的0.1%~0.2%。按照2021版世界卫生组织(world health organization, WHO)肺肿瘤组织学分类,该肿瘤属于唾液腺型肿瘤。该疾病临床表现及影像学无特异性,易被延误诊治,确诊需病理,分期尚无公认标准,治疗首选手术,术后或不能手术者可行放疗,单纯全身治疗(化疗、靶向、免疫)效果差。该文对TACC从命名和组织学分类、临床特征、影像学、病理、分期、治疗和预后共七个方面进行了综述。Primary tracheobronchial adenoid cystic carcinoma(TACC)is a rare type of non-small cell lung cancer,accounting for only 0.1%~0.2%of all lung malignancies.According to the 2021 World Health Organization(WHO)lung tumor histological classification,adenoid cystic carcinoma belongs to salivary gland tumors.The clinical manifestations and imaging of this type of disease are non-specific,often misdiagnosed and delayed treatment.Diagnosis requires pathology,and there is no recognized standard for staging.Sugery is the preferred treatment option.Radiotherapy is available for postoperative or inoperable patients,and the effect of systemic therapy(chemotherapy,targeted,immunization)is poor.This article reviews TACC from seven aspects,such as naming and histological classification,clinical features,imaging,pathology,staging,treatment and prognosis.

关 键 词：肺肿瘤 腺样囊性癌 病理 诊断 治疗 

分 类 号：R734.1[医药卫生—肿瘤]